Potential role of sorafenib in the treatment of acute myeloid leukemia

Leukemia and Lymphoma

Volumn 49, Issue 12, 2008, Pages 2246-2255

  Mori, Shahram ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Zhang, Weiguo ^a   Andreef, Michael ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AML; FLT3 mutations; MAP kinase signalling; Sorafenib

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; RAF PROTEIN; RAS PROTEIN; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA REMISSION; LEUKEMOGENESIS; LIVER CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL TRANSPLANTATION; TUMOR REGRESSION;

BENZENESULFONATES; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 57449110921     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802510349     Document Type: Review

References (77)

1. Jabbour, E. J., Estey, E. and Kantarjian, H. M. (2006) Adult acute myeloid leukemia. Mayo Clin Proc, 81, pp. 247-260.
2. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E. Blanc, J. F. et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, pp. 378-390.
3. Ricciardi, M. R., McQueen, T., Chism, D., Milella, M., Estey, E. Kaldjian, E. et al. (2005) Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia, 19, pp. 1543-1549.
4. Ravandi, F., Talpaz, M. and Estrov, Z. (2003) Modulation of cellular signaling pathways: Prospects for targeted therapy in hematological malignancies. Clin Cancer Res, 9, pp. 535-550.
5. Doepfner, K. T., Boller, D. and Arcaro, A. (2007) Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol, 63, pp. 215-230.
6. Milella, M., Kornblau, S. M., Estrov, Z., Carter, B. Z., Lapillonne, H. Harris, D. et al. (2001) Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest, 108, pp. 851-859.
7. Milella, M., Estrov, Z., Kornblau, S. M., Carter, B. Z., Konopleva, M. Tari, A. et al. (2002) Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood, 99, pp. 3461-3464.
8. Milella, M., Konopleva, M., Precupanu, C. M., Tabe, Y., Ricciardi, M. R. Gregorj, C. et al. (2007) MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood, 109, pp. 2121-2129.
9. Kornblau, S. M., Womble, M., Qiu, Y. H., Jackson, C. E., Chen, W. Konopleva, M. et al. (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood, 108, pp. 2358-2365.
10. Gilliland, D. G. and Griffin, J. D. (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood, 100, pp. 1532-1542.
11. Drexler, H. G. (1996) Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia, 10, pp. 588-599.
12. Lyman, S. D. (1998) Biologic effects and potential clinical applications of FLT3 ligand. Curr Opin Hematol, 5, pp. 192-196.
13. Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S. Rockwell, P. et al. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA, 91, pp. 459-463.
14. Kelly, L. M., Yu, J. C., Boulton, C. L., Apatira, M., Li, J. Sullivan, C. M. et al. (2002) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 1, pp. 421-432.
15. Dosil, M., Wang, S. and Lemischka, I. R. (1993) Mitogenic signalling and substrate specificity of the Flk2/FLT3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol, 13, pp. 6572-6585.
16. Lisovsky, M., Braun, S. E., Ge, Y., Takahira, H., Lu, L. Savchenko, V. G. et al. (1996) FLT3-ligand production by human bone marrow stromal cells. Leukemia, 10, pp. 1012-1018.
17. Lyman, S. D., Seaberg, M., Hanna, R., Zappone, J., Brasel, K. Abkowitz, J. L. et al. (1995) Plasma/serum levels of FLT3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood, 86, pp. 4091-4096.
18. Martelli, A. M., Tazzari, P. L., Evangelisti, C., Chiarini, F., Blalock, W. L. Billi, A. M. et al. (2007) Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: From bench to bedside. Curr Med Chem, 14, pp. 2009-2023.
19. Zeng, Z., Sarbassov dos, D, Samudio, I. J., Yee, K. W., Munsell, M. F. Ellen Jackson, C et al. (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood, 109, pp. 3509-3512.
20. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G. Albanese, C. et al. (1999) Stat3 as an oncogene. Cell, 98, pp. 295-303.
21. Ning, Z. Q., Li, J. and Arceci, R. J. (2001) Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood, 97, pp. 3559-3567.
22. Nakao, M., Janssen, J. W., Erz, D., Seriu, T. and Bartram, C. R. (2000) Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: A marker for the monitoring of minimal residual disease. Leukemia, 14, pp. 522-524.
23. Carow, C. E., Kim, E., Hawkins, A. L., Webb, H. D., Griffin, C. A. Jabs, E. W. et al. (1995) Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12-→q13. Cytogenet Cell Genet, 70, pp. 255-257.
24. Karsunky, H., Merad, M., Cozzio, A., Weissman, I. L. and Manz, M. G. (2003) FLT3 ligand regulates dendritic cell development from FLT3+ lymphoid and myeloid-committed progenitors to FLT3+ dendritic cells in vivo. J Exp Med, 198, pp. 305-313.
25. Kusadasi, N., Koevoet, J. L., van Soest, P. L. and Ploemacher, R. E. (2001) Stromal support augments extended long-term ex vivo expansion of hemopoietic progenitor cells. Leukemia, 15, pp. 1347-1358.
26. McKenna, H. J., Stocking, K. L., Miller, R. E., Brasel, K., De Smedt, T. Maraskovsky, E. et al. (2000) Mice lacking FLT3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood, 95, pp. 3489-3497.
27. Mackarehtschian, K., Hardin, J. D., Moore, K. A., Boast, S., Goff, S. P. and Lemischka, I. R. (1995) Targeted disruption of the flk2/FLT3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity, 3, pp. 147-161.
28. Zheng, R., Friedman, A. D. and Small, D. (2002) Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood, 100, pp. 4154-4161.
29. Veiby, O. P., Jacobsen, F. W., Cui, L., Lyman, S. D. and Jacobsen, S. E. (1996) The FLT3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. J Immunol, 157, pp. 2953-2960.
30. Rosnet, O., Buhring, H. J., Marchetto, S., Rappold, I., Lavagna, C. Sainty, D. et al. (1996) Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia, 10, pp. 238-248.
31. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U. Platzbecker, U. et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, pp. 4326-4335.
32. Griffith, J., Black, J., Faerman, C., Swenson, L., Wynn, M. Lu, F. et al. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell, 13, pp. 169-178.
33. Breitenbuecher, F., Schnittger, S., Grundler, R., Markova, B., Carius, B. Brecht, A. et al. Identification of a novel type of ITD mutations located in non-juxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood
34. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P. Wuchter, C. et al. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, pp. 59-66.
35. Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S. Okuda, T. et al. (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and MDS among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, 11, pp. 1605-1609.
36. Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S. Miyawaki, S. et al. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood, 93, pp. 3074-3080.
37. Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R. Muller, C. et al. (2000) FLT3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, 96, pp. 3907-3914.
38. Fenski, R., Flesch, K., Serve, S., Mizuki, M., Oelmann, E. Kratz-Albers, K. et al. (2000) Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol, 108, pp. 322-330.
39. Tse, K. F., Mukherjee, G. and Small, D. (2000) Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia, 14, pp. 1766-1776.
40. Radomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T. and Tenen, D. G. (1998) CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol, 18, pp. 4301-4314.
41. Ross, S. E., Radomska, H. S., Wu, B., Zhang, P., Winnay, J. N. Bajnok, L. et al. (2004) Phosphorylation of C/EBP alpha inhibits granulopoiesis. Mol Cell Biol, 24, pp. 675-686.
42. Wang, X., Scott, E., Sawyers, C. L. and Friedman, A. D. (1999) C/EBP alpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood, 94, pp. 560-571.
43. Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S. Schnittger, S. et al. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet, 27, pp. 263-270.
44. Wilhelm, S. and Chien, D. S. (2002) BAY 43-9006: Preclinical data. Curr Pharm Des, 8, pp. 2255-2257.
45. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A. Rong, H. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, pp. 7099-7109.
46. Druker, B. J. (2003) Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother, 4, pp. 963-971.
47. Lyons, J. F., Wilhelm, S., Hibner, B. and Bollag, G. (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer, 8, pp. 219-225.
48. Kang, B., Hao, C., Wang, H., Zhang, J., Xing, R. Shao, J. et al. (2008) Evaluation of hepatic-metastasis risk of colorectal cancer upon the protein signature of PI3K/AKT pathway. J Proteome Res, 7, pp. 3507-3515.
49. Steelman, L. S., Stadelman, K. M., Chappell, W. H., Horn, S., Basecke, J. Cervello, M. et al. (2008) Akt as a therapeutic target in cancer. Expert Opin Ther Targets, 12, pp. 1139-1165.
50. Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D. and Robertson, G. P. (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res, 65, pp. 2412-2421.
51. Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A. Wilkie, D. et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res, 66, pp. 11851-11858.
52. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J. Smith, R. A. et al. (2006) Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5, pp. 835-844.
53. Cohen, H. T. and McGovern, F. J. (2005) Renal-cell carcinoma. N Engl J Med, 353, pp. 2477-2490.
54. Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B. Rosner, G. L. et al. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, pp. 2505-2512.
55. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S. Siebels, M. et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, pp. 125-134.
56. Zhang, W., Konopleva, M., Shi, Y. X., Harris, D., Small, D. Ling, X. et al. (2006) Sorafenib (BAY 43-9006) directly targets FLT3-ITD in acute myelogenous leukemia. Blood, p. 108.
57. Auclair, D., Miller, D., Yatsula, V., Pickett, W., Carter, C. Chang, Y. et al. (2007) Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia, 21, pp. 439-445.
58. Baines, P., Fisher, J., Truran, L., Davies, E., Hallett, M. Hoy, T. et al. (2000) The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro. Eur J Haematol, 64, pp. 211-218.
59. James, J. A., Smith, M. A., Court, E. L., Yip, C., Ching, Y. Willson, C. et al. (2003) An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia. Hematol J, 4, pp. 427-432.
60. Zhang, W., Konopleva, M., Ruvolo, V. R., McQueen, T., Evans, R. L. Bornmann, W. G. et al. (2008) Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia, 22, pp. 808-818.
61. Adams, J. M. (2003) Ways of dying: Multiple pathways to apoptosis. Genes Dev, 17, pp. 2481-2495.
62. Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A. and Greenberg, M. E. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science, 286, pp. 1358-1362.
63. Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A. Kaufmann, S. H. et al. (2005) The role of MCL-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene, 24, pp. 6861-6869.
64. Zhang, W., Konopleva, M., Shi, Y. X., McQueen, T., Harris, D. Ling, X. et al. (2008) Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst, 100, pp. 184-198.
65. Tong, F. K., Chow, S. and Hedley, D. (2006) Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry B Clin Cytom, 70, pp. 107-114.
66. Delmonte, J. (2007) Update of a phase I study of Sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood, p. 110.
67. Safaian, N. N., Czibere, A., Bruns, I., Fenk, R., Reinecke, P. Dienst, A. et al. Sorafenib (Nexavar((R))) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD(+) acute myeloid leukemia. Leuk Res
68. Fried, W., Chamberlin, W., Kedo, A. and Barone, J. (1976) Effects of radiation on hematopoietic stroma. Exp Hematol, 4, pp. 310-314.
69. Domenech, J., Roingeard, F. and Binet, C. (1997) The mechanisms involved in the impairment of hematopoiesis after autologous bone marrow transplantation. Leuk Lymphoma, 24, pp. 239-256.
70. Konopleva, M., Konoplev, S., Hu, W., Zaritskey, A. Y., Afanasiev, B. V. and Andreeff, M. (2002) Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia, 16, pp. 1713-1724.
71. O'Farrell, A. M., Foran, J. M., Fiedler, W., Serve, H., Paquette, R. L. Cooper, M. A. et al. (2003) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res, 9, pp. 5465-5476.
72. Fiedler, W., Serve, H., Dohner, H., Schwittay, M., Ottmann, O. G. O'Farrell, A. M. et al. (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 105, pp. 986-993.
73. Jarvis, W. D., Fornari Jr, F. A., Tombes, R. M., Erukulla, R. K., Bittman, R. Schwartz, G. K. et al. (1998) Evidence for involvement of MAP kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling. Mol Pharmacol, 54, pp. 844-856.
74. Ravandi, F. and Estrov, Z. (2006) Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin Cancer Res, 12, pp. 340-344.
75. Li, L., Piloto, O., Kim, K. T., Ye, Z., Nguyen, H. B. Yu, X. et al. (2007) FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br J Haematol, 137, pp. 64-75.
76. Clark, J. J., Cools, J., Curley, D. P., Yu, J. C., Lokker, N. A. Giese, N. A. et al. (2004) Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. Blood, 104, pp. 2867-2872.
77. Cools, J., Mentens, N., Furet, P., Fabbro, D., Clark, J. J. Griffin, J. D. et al. (2004) Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia. Cancer Res, 64, pp. 6385-6349.